Early suPAR levels as a predictor of COVID-19 severity: A new tool for efficient patient triage - 29/05/25
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Highlights |
• | Early suPAR levels are strongly associated with severe COVID-19 progression. |
• | A single early suPAR measurement can predict unfavorable outcomes in COVID-19 patients. |
• | suPAR level measurement could enhance patient triage during seasonal COVID-19 resurgences. |
Abstract |
Background |
Following several waves of the COVID-19 pandemic, we are now facing a lower but persistent rate of SARS-CoV-2 infections, with seasonal resurgences often coinciding with other respiratory tract infections.
Objective |
We aimed to identify early clinico-biological variables predictive of an unfavorable outcome in patients with primary SARS-CoV-2 infection. We also evaluated the role of suPAR, an innovative biomarker, in predicting disease severity.
Methods |
We included 255 patients with PCR-confirmed primary SARS-CoV-2 infection and with a 30-day follow-up minimum. Blood samples were collected within the first 24 h of hospitalization to measure suPAR levels. Comprehensive data from medical records were analyzed to assess their predictive value in stratifying patients into seven severity groups, with groups 1 to 3 representing severe COVID-19 (death, intubation, ECMO, or non-invasive ventilation).
Results |
Early plasma suPAR levels were significantly associated with severe disease progression, as evidenced by ANOVA and logistic regression models, highlighting suPAR as a persistent predictive factor for unfavorable outcomes.
Conclusion |
Our findings suggest that a single suPAR measurement, performed early after a positive PCR test for SARS-CoV-2, holds strong predictive value for patient outcomes. This biomarker, alongside pulse oximetry and CT scan results, could be instrumental in early patient triage during seasonal COVID-19 resurgences.
Le texte complet de cet article est disponible en PDF.Keywords : suPAR, SARS-CoV-2 primoinfection, Predictive models
Plan
Vol 55 - N° 4
Article 105058- juin 2025 Retour au numéro
Article précédent
- The latest updates on the proper use of fluoroquinolones – Actualisation 2025 update by the SPILF and the GPIP
- F. Vuotto, J.P. Bru, E. Canoui, M. Caseris, M.C.C. Chopin, R. Cohen, S. Diamantis, A. Dinh, P. Fillatre, R. Gauzit, Y. Gillet, A.P. Jonville-Bera, M. Lafaurie, P. Lesprit, M. Lorrot, J. Lourtet, L. Maulin, D. Poitrenaud, A. Pariente, J. Raymond, C. Strady, J.P. Stahl, E. Varon, Y. Welker, E. Bonnet
- HLA-A*03 may confer protection against long COVID through an enhanced immune response
- Eduardo Pons-Fuster, Rodrigo Martinez-Rodriguez, Lourdes Gimeno-Arias, M.J. Alcaraz, Marta Moreno, Jose M. Gómez, Ana Pelaez, Elisa García, Cristina Tomás, Angeles Muñoz, María V. Martínez-Sánchez, Inmaculada Ruiz-Lorente, Diana Ceballos, Alfredo Minguela, Enrique Bernal
Bienvenue sur EM-consulte, la référence des professionnels de santé.